Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Packer

Showing results (251-260 of 4,797) with videos related to

Pageof 480
Sort By:
Diabetes Care|February 22, 2020
SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of ActionMilton Packer
Cardiovascular Drugs and Therapy|January 1, 1989
Does digitalis work in chronic heart failure? The end of a 200-year-old controversyM Packer
Journal of Cardiovascular Pharmacology|January 1, 1987
Converting-enzyme inhibition in the management of severe chronic congestive heart failure: physiologic conceptsM Packer
Journal of the American Heart Association|August 14, 2020
Molecular, Cellular, and Clinical Evidence That Sodium-Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart FailureMilton Packer
European Journal of Heart Failure|April 4, 2023
A reclassification of heart failure based on recognition of heart failure with normal to supernormal ejection fraction, a clinically common form of cardiac contracture, with distinctive pathophysiological and therapeutic featuresMilton Packer
Journal of the American Society of Nephrology : JASN|June 21, 2023
Fetal Reprogramming of Nutrient Surplus Signaling, O-GlcNAcylation, and the Evolution of CKDMilton Packer
Circulation. Heart Failure|September 8, 2020
Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) InhibitorsMilton Packer
Circulation|March 14, 2020
Role of Deranged Energy Deprivation Signaling in the Pathogenesis of Cardiac and Renal Disease in States of Perceived Nutrient OverabundanceMilton Packer
Diabetes, Obesity & Metabolism|February 23, 2018
Higher mortality rate in patients with heart failure who are taking commonly prescribed antidiabetic medications and achieve recommended levels of glycaemic controlMilton Packer
Clinical Ophthalmology (Auckland, N.Z.)|June 30, 2016
Meta-analysis and review: effectiveness, safety, and central port design of the intraocular collamer lensMark Packer
Pageof 480

Showing results (251-260 of 4,797) with videos related to

Sort By:
Pageof 480
Diabetes Care|February 22, 2020
SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of ActionMilton Packer
Cardiovascular Drugs and Therapy|January 1, 1989
Does digitalis work in chronic heart failure? The end of a 200-year-old controversyM Packer
Journal of Cardiovascular Pharmacology|January 1, 1987
Converting-enzyme inhibition in the management of severe chronic congestive heart failure: physiologic conceptsM Packer
Journal of the American Heart Association|August 14, 2020
Molecular, Cellular, and Clinical Evidence That Sodium-Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart FailureMilton Packer
European Journal of Heart Failure|April 4, 2023
A reclassification of heart failure based on recognition of heart failure with normal to supernormal ejection fraction, a clinically common form of cardiac contracture, with distinctive pathophysiological and therapeutic featuresMilton Packer
Journal of the American Society of Nephrology : JASN|June 21, 2023
Fetal Reprogramming of Nutrient Surplus Signaling, O-GlcNAcylation, and the Evolution of CKDMilton Packer
Circulation. Heart Failure|September 8, 2020
Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) InhibitorsMilton Packer
Circulation|March 14, 2020
Role of Deranged Energy Deprivation Signaling in the Pathogenesis of Cardiac and Renal Disease in States of Perceived Nutrient OverabundanceMilton Packer
Diabetes, Obesity & Metabolism|February 23, 2018
Higher mortality rate in patients with heart failure who are taking commonly prescribed antidiabetic medications and achieve recommended levels of glycaemic controlMilton Packer
Clinical Ophthalmology (Auckland, N.Z.)|June 30, 2016
Meta-analysis and review: effectiveness, safety, and central port design of the intraocular collamer lensMark Packer
Pageof 480